DEVELOPMENT OF CD109 AS A NOVEL TGF-BETA ANTAGONIST AND ANTI-FIBROTIC AGENT FOR THE TREATMENT OF SCLERODERMA
$1,003,844FY2013Department of DefenseDOD
The Research Institute Of The Mcgill University Health Centre
The Research Institute Of The Mcgill University Health Centre